Clinical trial
A Phase 1b Dose Escalation Study of the Histone Deacetylase Inhibitor (HDACi) JNJ-26481585 in Combination With VELCADE (Bortezomib) and Dexamethasone for Subjects With Relapsed Multiple Myeloma
NCT01464112 is registered in ClinicalTrials.gov with Janssen Research & Development, LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1b Dose Escalation Study of the Histone Deacetylase Inhibitor (HDACi) JNJ-26481585 in Combination With VELCADE (Bortezomib) and Dexamethasone for Subjects With Relapsed Multiple Myeloma
- Lead sponsor
- Janssen Research & Development, LLC
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- September 16, 2011
- Completion date
- November 19, 2013
- Enrollment
- 18 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.